Sp1198

EMERGING BLOOD BASED COLORECTAL CANCER SCREENING TESTS

Date
May 9, 2023
Explore related products in the following collection:

Society: AGA

Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc). This session will provide expert guidance on the tests and their appropriate use in clinical care. LIVE STREAM SESSION

Presenter


Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
Review updates and current considerations in colon cancer screening and surveillance related topics…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for ITS TOO EARLY TO LENGTHEN SURVEILLANCE INTERNALS
ITS TOO EARLY TO LENGTHEN SURVEILLANCE INTERNALS
Review updates and current considerations in colon cancer screening and surveillance related topics…